Despite this, repeated clinical trials of IGF1R inhibitors, both monoclonal antibodies and small-molecule tyrosine kinase inhibitors, have failed to show clinical efficacy, either alone or in combinations, against several cancer types [20, 21]. Here, IGF1R is linked to cancer.